Overcoming Access Issues: Advocacy and Assistance Programs

Barbra Goshko, MSN, APRN, FNP-BC University of Louisville July 28, 2015



Disclosures

- Advisory Boards:
 - Janssen, Gilead, AbbVie
- Speaker Bureaus:
 - Janssen, Gilead, AbbVie, Bristol-Myers Squibb, Entera Health, Salix





Outline

- Assess patient readiness for treatment
- Examine various treatment obstacles
- Discuss Advocacy and Assistance Programs





Assessing treatment readiness

- Patient willingness
- Substance abuse
- Medication reconciliation
- Co-morbidity control
- Insurance

- Insurance Plan Guidelines for readiness:
 - Mental Health evaluation
 - Drug screens
 - Pregnancy
 - Disease severity prioritization



Disease Severity Prioritization

- Based on AASLD Guidelines
- Cirrhosis/Fibrosis
- HCV-influenced comorbidities (cryoglubulinemia, porphyria cutanea tarda, NASH)
- Co-infection status







Once readiness is established...

- Provider prescribes HCV antiviral therapy based on
 - AASLD Guidelines
 - Plan formulary
 - Drug labeling
 - Patient wishes


• But what really happens?







The Hepatitis C Drug Flow



Obstacle 1: Prior Authorization

- Typically used on high cost medications
- Helps plans ensure medications are being used for reasonable purposes (supported by data)
- Can take place the same day as requested
- May take substantially longer periods of time
- Vary in length of information requested
- Can be initialized in the office, by the pharmacy, prescriber, etc.
- Can be completed by trained staff



Obstacle 2: Denials

- The Insurance Plan (Humana, Anthem, Cigna, etc.)
- The Pharmacy Benefits Administrator (Magellan, Caremark, Express Scripts, etc.)
- The Group Funded Plan (Ford, UPS, UofL)



Why Deny?

- Drug/Alcohol use/abuse
 - Past or Present
- "Not sick enough"
 - F0-F2 vs. F3-F4
- Missing information
 - Past treatment
 - Viral load, genotype

- Formulary
- One treatment per lifetime



Obstacle 3: Appeals

- Phone call to a Medical Director
- Appeals letter
 - Discuss health benefit to the patient
 - May reduce need for liver transplantation and risk of liver cancer
 - Provider may give more detail than on PA
 - Make the case for a non-preferred drug
 - Drug-Drug interactions
 - Past intolerance, allergy
 - Contraindications



The real obstacle:





Time to Tablet

•Median: 45 days

• A change in insurance may re-start the clock













Pharmaceutical Assistance Programs

Who?

- Gilead
- sovaldi.com; harvoni.com
- AbbVie
- viekira.com/proceed-program
- Janssen
- janssenaccessone.com/pages/olysio/

- Merck
- www.merckhelps.com/pegintron
- Kadmon
- drtms.net/Kadmon/Ribapak/Consu mer.aspx
- Genentech
- www.pegasys.com/patient/resour ces/



Daklinza (daclatasvir)

Approved Friday, July 24, 2015 Patient Support CONNECT Program Patientsupportconnect.com





What do they do for the Provider?

For the Provider

- Prior Authorization assistance
- Coverage determination
- Linkage to Specialty Pharmacy
- Appeals support





What do the do for the Patient?

- Copay assistance
- Refill reminders
- 24/7 Nursing Hotline
- Linkage to Foundation Assistance
- Free medication





Portal Programs

Who has them?

- Pharmaceutical Companies
- Insurance Companies
- Independent Companies

Examples

- Abbie: Pro<u>C</u>eed Clinical Portal
- Humana, Anthem, etc.
- iAssist, CoverMyMeds



What do they do?

- Online access to Prior Authorization forms
- Tracking
 - PA status, shipment status, start dates, needed documentation
- Live Chat
- Faster response times
 - Instant notification in many cases





Patient Advocacy Resources

- Hepatitis C Advocate
 - www.hepcadvocate.org
- Patient Advocate Foundations Hepatitis C line
 - www.hepatitisc.pafcareline.org 800-532-5274
- Patient Access Network Foundation
 - www.PANfoundation.org 866-316-7263
- Partnership for Prescription Assistance
 - <u>www.pparx.org</u> 888-477-2669



What do they do?

- Provide patient-based education
- Applications for financial assistance
- Help with appeals, questions to ask your provider, etc.
- Links to community-based support groups and state Hepatitis coordinators
- Access to clinical trials



Summary

- Safe, effective cures for Hepatitis C exist for treatment-ready patients
- Obstacles may prevent, limit, or slow access
- Advocates exist in many areas
- Patience!



